Trial Search Results
Long Term Follow-Up Study for Subjects Previously Treated With Algenpantucel-L (HyperAcute-Pancreas) Immunotherapy
This protocol (NLG0705) provides a mechanism for the 15-year follow-up period that the FDA requires for all participants in gene transfer protocols and assures that adequate follow-up can be maintained for subjects who have received at least one dose of algenpantucel-L.
Stanford is currently not accepting patients for this trial.
NewLink Genetics Corporation
- Receipt of at least one dose of algenpantucel-L within the past 15 years
- Signed consent
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study